Compass Therapeutics, Inc.

NASDAQ:CMPX

Biotechnology

Healthcare
$0.61 -1.46%

-$0.03 today

Market cap
$110.03M
Beta
0.74
P/E (TTM)
-5.5
EPS (TTM)
-$0.37
52W Low $1.61High $6.88

Volume 1.79M

Average 7.64M

CMPX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Compass Therapeutics, Inc.NASDAQ: CMPX

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 186.4M shares rose 34.8% year over year, ahead of the +17.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +14.5% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +34.8% holds above the trailing-twelve-month pace of +17.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
186.4M+0.8% QoQ
Last fiscal yearDec 2025
157.7M+15.0% YoY
LTMMar 2026
161.95M+17.8% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+34.8%——
1 year+15.0%——
3-year CAGR+14.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
157.7M USD
Year-over-year change
+15.0%
4-year CAGR
+25.8%

Weighted Avg Shares vs competitors

How CMPX compares with its peers on the latest reported figures

  • CMPX's LTM Mar 2026 weighted avg shares of 161.95M shares is the 4th highest of the 11 companies compared; the peer median is 67.79M shares.
  • Its year-over-year change of +17.8% is the 2nd highest of 10, against a peer median of +7.9%.
  • Over three fiscal years its annual growth of +14.5% compares with a peer median of +19.3%.
CMPX Competitors Peer median
Weighted Avg Shares for CMPX and competitors
Company Period LTM YoY 3-year CAGR
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026372.59M +6.8%+29.9%
OCGNOcugen, Inc.LTM Mar 2026307.2M +9.9%+11.8%
GOSSGossamer Bio, Inc.LTM Mar 2026229M +1.1%+39.3%
CMPXCompass Therapeutics, Inc.LTM Mar 2026161.95M +17.8%+14.5%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 202682.39M +23.5%+19.3%
BCYCBicycle Therapeutics plcLTM Mar 202669.4M +7.1%+32.7%
FULCFulcrum Therapeutics, Inc.LTM Mar 202666.18M +9.8%+12.1%
OMEROmeros CorporationLTM Mar 202665.07M +12.1%+0.4%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 202659.51M +7.9%+21.4%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 202552.2M ——
MNPRMonopar Therapeutics Inc.LTM Mar 20267.34M -28.8%-16.5%
Peer median (excluding CMPX) 67.79M+7.9%+19.3%

Competitors are the stored peer set for CMPX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000850K0
Cost of Revenue00001.47M
Gross Profit000850K(1.47M)
Gross Margin———100.0%—
Research & Development20.34M30M38.12M42.34M55.97M
Selling, General & Admin10.93M11.66M12.24M15.13M16.87M
Operating Expenses81.88M41.66M50.36M57.48M71.37M
Depreciation & Amortization1.62M1.9M1.89M1.75M1.47M
EBITDA(80.19M)(34.96M)(40.6M)(47.62M)(65.02M)
EBITDA Margin———-5602.6%—
Operating Income(81.88M)(41.66M)(50.36M)(56.63M)(72.84M)
Operating Margin———-6661.8%—
Interest Income29K2.36M7.9M7.3M6.35M
Interest Expense370K2.36M000
Other Income / Expenses(299K)2.43M7.87M7.25M6.35M
Income Before Tax(82.18M)(39.23M)(42.49M)(49.38M)(66.49M)
Pre-Tax Margin———-5808.8%—
Income Tax Expense00000
Net Income(82.18M)(39.23M)(42.49M)(49.38M)(66.49M)
Net Margin———-5808.8%—
EPS (Basic)(1.31)(0.35)(0.33)(0.36)(0.42)
EPS (Diluted)(1.31)(0.35)(0.33)(0.36)(0.42)
Weighted Avg Shares62.87M105.19M127.03M137.11M157.7M
Weighted Avg Shares (Diluted)62.87M105.19M127.03M137.11M157.7M

Compass Therapeutics, Inc.

NASDAQ:CMPX

Intrinsic Alpha fair value

Locked

Current Price

$0.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.